Adaptimmune Therapeutics (NASDAQ:ADAP) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Adaptimmune Therapeutics (NASDAQ:ADAP) in a research note issued to investors on Thursday morning. The brokerage issued a buy rating on the biotechnology company’s stock.

Several other equities research analysts have also issued reports on ADAP. Mizuho dropped their price objective on Adaptimmune Therapeutics from $3.00 to $1.50 and set an “outperform” rating for the company in a research note on Wednesday, November 27th. HC Wainwright dropped their price target on Adaptimmune Therapeutics from $4.00 to $3.50 and set a “buy” rating for the company in a research note on Thursday, November 14th. Finally, Guggenheim dropped their price target on Adaptimmune Therapeutics from $4.00 to $3.00 and set a “buy” rating for the company in a research note on Friday, November 15th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Adaptimmune Therapeutics presently has an average rating of “Buy” and an average price target of $2.79.

Adaptimmune Therapeutics Price Performance

Adaptimmune Therapeutics stock opened at $0.45 on Thursday. Adaptimmune Therapeutics has a one year low of $0.44 and a one year high of $1.65. The business has a fifty day moving average price of $0.57 and a 200-day moving average price of $0.73. The company has a debt-to-equity ratio of 0.62, a current ratio of 3.85 and a quick ratio of 3.82. The firm has a market capitalization of $115.22 million, a P/E ratio of -2.05 and a beta of 2.52.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of ADAP. GSA Capital Partners LLP purchased a new position in shares of Adaptimmune Therapeutics in the third quarter worth about $95,000. FMR LLC increased its holdings in Adaptimmune Therapeutics by 3.0% during the 3rd quarter. FMR LLC now owns 1,740,900 shares of the biotechnology company’s stock valued at $1,655,000 after purchasing an additional 50,419 shares during the period. Jane Street Group LLC increased its holdings in Adaptimmune Therapeutics by 130.4% during the 3rd quarter. Jane Street Group LLC now owns 174,157 shares of the biotechnology company’s stock valued at $166,000 after purchasing an additional 98,581 shares during the period. Virtu Financial LLC increased its holdings in Adaptimmune Therapeutics by 27.5% during the 3rd quarter. Virtu Financial LLC now owns 101,008 shares of the biotechnology company’s stock valued at $96,000 after purchasing an additional 21,769 shares during the period. Finally, LPL Financial LLC increased its holdings in Adaptimmune Therapeutics by 106.5% during the 4th quarter. LPL Financial LLC now owns 183,479 shares of the biotechnology company’s stock valued at $99,000 after purchasing an additional 94,623 shares during the period. Hedge funds and other institutional investors own 31.37% of the company’s stock.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.